V. Mathew et al., The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions, J AM COL C, 34(4), 1999, pp. 1163-1169
Citations number
28
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
OBJECTIVES The purpose of this study was to evaluate the effect of abcixima
b use on clinical outcome in aortocoronary vein graft interventions.
BACKGROUND Although large randomized trials have demonstrated a significant
benefit of abciximab use in the setting of percutaneous coronary intervent
ions, there is relatively little data with respect to the use of this agent
in percutaneous vein graft interventions.
METHODS Three hundred and forty-three patients were identified; 210 undergo
ing vein graft intervention without abciximab and 133 patients with abcixim
ab.
RESULTS There were differences in baseline clinical and angiographic charac
teristics between the two groups; advanced age, unstable angina, older vein
grafts and thrombus containing lesions were relatively common in both grou
ps. Angiographic and procedural success rates were similar with or without
the use of abciximab (89% vs. 92%, p = 0.15, and 85% vs. 91%, p = 0.12, res
pectively). The in-hospital composite end point of death/Q-wave myocardial
infarction (QWMI)/repeat revascularization was similar between the two grou
ps. Utilizing statistical modeling to adjust for baseline differences betwe
en the groups, abciximab use did not influence the cumulative long-term com
posite end point of death/MI/repeat revascularization.
CONCLUSIONS This study demonstrates that in this relatively high-risk popul
ation undergoing aortocoronary vein graft interventions, the administration
of abciximab periprocedurally does not appear to reduce major adverse clin
ical events. (J Am Coll Cardiol 1999;34:1163-9) (C) 1999 by the American Co
llege of Cardiology.